drugset / Trial / NCT00832884
The Safety of Intravenous Lacosamide
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of IV Lacosamide in children with partial-onset epilepsy, ages 4-35 years old, inclusive, who are either unable to take oral medication or require intravenous administration of IV Lacosamide.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-05
- Completion
- 2012-11
Publications
- Results Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008 Mar;49(3):418-24. doi: 10.1111/j.1528-1167.2007.01317.x. Epub 2007 Sep 19.
- Results Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001 Jan;43(1):11-58. doi: 10.1016/s0920-1211(00)00171-6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lacosamide | Other / unclassified | 0.7 mg/kg | Intravenous |
| Comparator | Lacosamide | Other / unclassified | 1.4 mg/kg | Intravenous |
| Comparator | Lacosamide | Other / unclassified | 2.1 mg/kg | Intravenous |
| Comparator | Lacosamide | Other / unclassified | 2.9 mg/kg | Intravenous |